Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 28Leukemia, Lymphocytic, Chronic, B-Cell 14Myelodysplastic Syndromes 6Waldenstrom Macroglobulinemia 5Lymphoma, B-Cell, Marginal Zone 5Burkitt Lymphoma 5Lymphoma, Mantle-Cell 4Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Recurrence 2Neoplasms 2Myeloproliferative Disorders 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2Leukemia 2Hematologic Neoplasms 2Blast Crisis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Follicular 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1GATA2 Deficiency 1Anemia, Refractory, with Excess of Blasts 1

Interventions

asciminib 2venetoclax 1gilteritinib 1fludarabine phosphate 1fludarabine 1blinatumomab 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Idarubicin 1Hyperbaric Oxygenation 1Filgrastim 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid × venetoclax × 30 days × Clear all
NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡